Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.60 |
| ▸ | ACE | P12821 | 7/20 | 0.56 |
| ▸ | NPY1R | P25929 | 1/20 | 0.56 |
| ▸ | NPY2R | P49146 | 1/20 | 0.56 |
| ▸ | NPY4R | P50391 | 1/20 | 0.56 |
| ▸ | MME | P08473 | 3/20 | 0.53 |
| ▸ | CPA1 | P15085 | 2/20 | 0.53 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.53 |
| ▸ | BACE1 | P56817 | 6/20 | 0.51 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL73897 | 0.97 | NPY4R (0.60) | FOLH1ACENPY1RNPY2RNPY4R | |
| SCHEMBL11056714 | 0.93 | FOLH1 (0.69) | FOLH1ACENPY1RNPY2RNPY4R | |
| SCHEMBL2474675 | 0.93 | FOLH1 (0.69) | FOLH1ACENPY1RNPY2RNPY4R | |
| SCHEMBL31067318 | 0.93 | FOLH1 (0.69) | FOLH1ACENPY1RNPY2RNPY4R | |
| SCHEMBL31636210 | 0.92 | BACE1 (0.55) | FOLH1ACENPY1RNPY2RNPY4R | |
| SCHEMBL30464728 | 0.92 | NPY1R (0.60) | FOLH1ACENPY1RNPY2RNPY4R | |
| Hydrochloric Acid SCHEMBL6473764 | 0.92 | FOLH1 (0.67) | FOLH1ACENPY1RNPY2RNPY4R | |
| SCHEMBL32681297 | 0.91 | FOLH1 (0.60) | FOLH1ACENPY1RNPY2RNPY4R | |
| SCHEMBL30445563 | 0.91 | OPRD1 (0.54) | FOLH1ACEMMECPA1ACE2 | |
| SCHEMBL30445840 | 0.91 | OPRD1 (0.54) | FOLH1ACEMMECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220267372-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | ONYX PHARMACEUTICALS, INC. | 2022-08-25 | — | — | US | disclosed |
| WO-2022170196-A1 | BINDING PEPTIDES AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-08-11 | — | — | WO | disclosed |
| US-20210179663-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | PROTEOLIX, INC. | 2021-06-17 | — | — | US | disclosed |
| US-20200325172-A1 | Compounds for proteasome enzyme inhibition | PROTEOLIX, INC. | 2020-10-15 | — | — | US | disclosed |
| US-20200071356-A1 | COMPOUNDS FOR PROTEASOME | PROTEOLIX, INC. | 2020-03-05 | — | — | US | disclosed |
| US-20190211058-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | PROTEOLIX, INC. | 2019-07-11 | — | — | US | disclosed |
| US-10150794-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2018-12-11 | — | — | US | disclosed |
| US-20180170962-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | ONYX THERAPEUTICS INC (US) | 2018-06-21 | — | — | US | disclosed |
| EP-3101026-B1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | ONYX THERAPEUTICS INC (US) | 2018-03-28 | — | — | EP | disclosed |
| US-20170260230-A1 | COMPUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS INC (US) | 2017-09-14 | — | — | US | disclosed |
| US-7417042-B2 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| EP-1948678-A1 | COMPOUNDS FOR ENZYME INHIBITION | Proteolix, Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20080090785-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| WO-2007056464-A1 | COMPOUNDS FOR ENZYME INHIBITION | PROTEOLIX, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070105786-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| EP-1781688-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | Proteolix, Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| EP-1758921-A2 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | Proteolix, Inc. (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006017842-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | PROTEOLIX, INC. (US) | 2006-02-16 | — | — | WO | disclosed |
| US-20060030533-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2006-02-09 | — | — | US | disclosed |
| WO-2005111008-A2 | COMPOUNDS FOR ENZYME INHIBITION | PROTEOLIX, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220267372-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | PSMB1, PSMB9, PSMB11 | FOLH1 1692/4885ACE 315/4885NPY1R 3368/4885 |
| US-20180170962-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | PSMB1, PSMB9, PSMB3 | FOLH1 1772/4885ACE 347/4885NPY1R 3351/4885 |
| US-20200071356-A1 | COMPOUNDS FOR PROTEASOME | PSMB1, PSMB9, PSMB2 | FOLH1 2012/4885ACE 918/4885NPY1R 3789/4885 |
| US-20080090785-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | ANPEP, DNPEP, CPN1 | FOLH1 1094/4885ACE 484/4885NPY1R 2267/4885 |
| US-20070105786-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | ANPEP, PSMB1, PSMB3 | FOLH1 1285/4885ACE 611/4885NPY1R 3068/4885 |
| US-20200325172-A1 | Compounds for proteasome enzyme inhibition | PSMB1, PSMB9, PSMB3 | FOLH1 1772/4885ACE 347/4885NPY1R 3351/4885 |
| US-20190211058-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | PSMB1, PSMB9, PSMB3 | FOLH1 1772/4885ACE 347/4885NPY1R 3351/4885 |
| US-20170260230-A1 | COMPUNDS FOR ENZYME INHIBITION | ANPEP, PSMB1, CPN1 | FOLH1 693/4885ACE 527/4885NPY1R 4037/4885 |
| US-20210179663-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | PSMB1, PSMB9, PSMB3 | FOLH1 1772/4885ACE 347/4885NPY1R 3351/4885 |
| US-10150794-B2 | Compounds for enzyme inhibition | ANPEP, HPN, DNPEP | FOLH1 873/4885ACE 433/4885NPY1R 3660/4885 |
| US-20060030533-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | ANPEP, DNPEP, CPN1 | FOLH1 1100/4885ACE 479/4885NPY1R 2271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.